Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH) by Yoneda, Masato et al.
BioMed  Central
Page 1 of 9
(page number not for citation purposes)
BMC Gastroenterology
Open Access Research article
Plasma Pentraxin3 is a Novel Marker for Nonalcoholic 
Steatohepatitis (NASH)
Masato Yoneda†1, Takashi Uchiyama†1, Shingo Kato1, Hiroki Endo1, 
Koji Fujita1, Kyoko Yoneda1, Hironori Mawatari1, Hiroshi Iida1, 
Hirokazu Takahashi1, Hiroyuki Kirikoshi1, Masahiko Inamori1, 
Yuichi Nozaki1, Noritoshi Kobayashi1, Kensuke Kubota1, Satoru Saito1, 
Shiro Maeyama2, Mina Sagara3, Hiroyuki Aburatani4, Tatsuhiko Kodama5 
and Atsushi Nakajima*1
Address: 1Division of Gastroenterology, Yokohama City University Graduate School of Medicine, 3-9 Fuku-ura, Yokohama, Japan, 2Kitakashiwa 
Rehabilitation Hospital, 265 Kashiwashita, Kashiwa, Japan, 3Perseus Proteomics Inc., 4-7-6 Komaba, Meguro-ku, Tokyo, Japan, 4Geneme Science 
Division, Research Center for Advanced Science and Technology, Graduate School of Medicine, The University of Tokyo, 4-6-1 Komaba, Meguro-
ku, Tokyo, Japan and 5Laboratory for Systems Biology and Medicine, Research Center for Advanced Science and Technology, Graduate School of 
Medicine, The University of Tokyo, 4-6-1 Komaba, Meguro-ku, Tokyo, Japan
Email: Masato Yoneda - yoneda@med.yokohama-cu.ac.jp; Takashi Uchiyama - maruru0203@yahoo.co.jp; 
Shingo Kato - shingo800m@hotmail.com; Hiroki Endo - t066011b@yokohama-cu.ac.jp; Koji Fujita - kfujita@yokohama-cu.ac.jp; 
Kyoko Yoneda - t066044g@yokohama-cu.ac.jp; Hironori Mawatari - mawatari-ykh@umin.ac.jp; Hiroshi Iida - hiro19780905@yahoo.co.jp; 
Hirokazu Takahashi - hirokazu@med.yokohama-cu.ac.jp; Hiroyuki Kirikoshi - hkirikos@med.yokohama-cu.ac.jp; 
Masahiko Inamori - inamorim@med.yokohama-cu.ac.jp; Yuichi Nozaki - nzaki-y@fukuhp.yokohama-cu.ac.jp; 
Noritoshi Kobayashi - norikoba@yokohama-cu.ac.jp; Kensuke Kubota - kubotak@yokohama-cu.ac.jp; Satoru Saito - ssai1423@yokohama-
cu.ac.jp; Shiro Maeyama - shiromaeyama915@msg.biglobe.ne.jp; Mina Sagara - msagara@ppmx.com; Hiroyuki Aburatani - haburata-
tky@umin.ac.jp; Tatsuhiko Kodama - kodama@lsbm.org; Atsushi Nakajima* - nakajima-tky@umin.ac.jp
* Corresponding author    †Equal contributors
Abstract
Background: The changes in the liver in nonalcoholic fatty liver disease (NAFLD) range over a
wide spectrum, extending from steatosis to steatohepatitis (NASH). However it has remained
difficult to differentiate between NASH and non-progressive NAFLD on the basis of the clinical
findings alone.
Aims: In this study we investigated the clinical usefulness of plasma Pentraxin3 (PTX3) levels to
predict NASH. Plasma PTX3 was measured in 70 patients with histologically verified NAFLD (28
with non-NASH and 42 with NASH) and 10 healthy control subjects.
Results: The plasma PTX3 level was significantly higher in the NASH cases than in the non-NASH
cases (p = 0.0021) and control subjects (p = 0.045). And the plasma PTX3 level was significantly
higher in the stages 3–4 NAFLD cases than in the stages 0–2 NAFLD cases (p < 0.0001). The PTX3
values were closely correlated with the stages of liver fibrosis (p < 0.0001, Kruskal-Wallis test). To
detect NASH compared with non-NASH, the area under the curve for plasma PTX3 were 0.755,
and to detect stages 3–4 NAFLD compared with stages 0–2 NAFLD, the area under the curve for
plasma PTX3 were 0.850.
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Conclusion: This is the first study to demonstrate consistent and profound elevation of plasma
PTX3 levels in NASH in comparison with non-NASH. The results suggest that plasma PTX3 levels
may not only be laboratory values that differentiate NASH from non-NASH, but marker of the
severity of hepatic fibrosis in NASH.
Background
Nonalcoholic fatty liver disease (NAFLD) is one of the
most common causes of chronic liver injury in many
countries around the world [1,2]. It represents a spectrum
of conditions that are histologically characterized by mac-
rovesicular hepatic steatosis, and the diagnosis is made in
patients who have not consumed alcohol in amounts suf-
ficient to be considered harmful to the liver. The histolog-
ical changes range over a wide spectrum, extending from
simple steatosis, which is generally non-progressive, to
nonalcoholic steatohepatitis (NASH), liver cirrhosis, liver
failure, and sometimes even hepatocellular carcinoma
[3,4]. Liver biopsy is recommended as the gold standard
for both the diagnosis and staging of fibrosis in NASH
patients [1,4,5], but it is invasive [6] and avoidance of
liver biopsy would be desirable. Several clinical studies
have attempted to identify serum markers that correlate
with the severity of liver fibrosis in NASH patients. Many
clinical variables have been proposed as predictors of
severe fibrosis in NAFLD patients, including old age,
underlying type 2 diabetes mellitus, obesity, serum
transaminase level, platelet count, etc [7-9].
We have previously reported that measurement of the
serum high-sensitivity C-reactive protein (CRP) level is
clinically useful for the diagnosis of NASH [10]. CRP and
serum amyloid P component (SAP) are well known mem-
bers of the pentraxin family of proteins, which is subdi-
vided into two subclasses according the length and
structure of the molecules: long and short. The classical
short PTXs, CRP and serum amyloid P, are acute-phase
proteins in humans [11], that are produced in the liver in
response to inflammatory mediators, most prominently
IL-6. Long PTXs are characterized by an unrelated N-ter-
minal domain coupled to a PTX-like C-terminal domain
[12,13]. The prototypic long PTX3 is rapidly produced in
response to Toll-like receptor engagement, tumor necrosis
factor-α, and IL-1β and released by diverse cell types,
including monocytes/macrophages, endothelial cells, vas-
cular smooth muscle cells, fibroblasts, and adipocytes
[14-19]. Plasma PTX3 levels have recently been found to
be elevated in patients with vasculitis [20], acute myocar-
dial infarction [21,22], and systemic inflammation or sep-
sis [23], however, there is no information about changes
in PTX3 levels in NAFLD or NASH patients. We hypothe-
sized that plasma PTX3 levels increase in patients with
NASH, and investigated the clinical usefulness for the
diagnosis and staging of liver fibrosis in NASH patients.
Methods
Patients
70 Japanese NAFLD patients (42 NASH and 28 non-
NASH) and 10 healthy control subjects were recruited. All
control subjects were confirmed to have normal liver
function and no viral hepatitis infection or alcoholics. All
of the 70 NAFLD patients were performed liver biopsy.
The study was conducted with the approval of the Ethics
Committee of Yokohama City University.
A detailed history was obtained and a physical examination
performed on all the 70 NAFLD patients. The histological
criteria for the diagnosis of NAFLD are the presence of mac-
rovesicular fatty change in hepatocytes with displacement
of the nucleus to the edge of the cell [24]. The criteria for
exclusion from participation in the study: history of hepatic
disease, such as chronic hepatitis C or concurrent active
hepatitis B (serum positive for hepatitis B surface antigen),
autoimmune hepatitis, primary biliary cirrhosis (PBC),
sclerosing cholangitis, hemochromatosis, α1-antitrypsin
deficiency, Wilson's disease, and current or past consump-
tion of more than 20 g of alcohol daily. No patients had
taken medicine which cause fatty liver, such as amiodar-
one, diltiazem, tamoxifen, steroids [24]. None of the
patients had any clinical evidence of hepatic decompensa-
tion, such as hepatic encephalopathy, ascites, variceal
bleeding, or elevated serum bilirubin level to more than
twofold the upper limit of normal. Patients with heart fail-
ure or autoimmune rheumatic disease, which have been
suggested to increase plasma PTX3 levels [25,26], and
patients with a history of treatment with statins, which
reduce plasma PTX3 levels [27], were also excluded.
Clinical and laboratory evaluation
Body weight and height were measured with a calibrated
scale after requesting the patients to remove their shoes
and any heavy clothing. Whole blood from 70 NAFLD
patients and 10 healthy control subjects was immediately
collected into a tube containing ethylene diaminetetraac-
etate (EDTA), and after centrifugation at 1500 × g for 15
min at room temperature, the plasma was frozen, and
stored at -80°C until analyzed. Serum samples were
obtained from 70 NAFLD patients after an overnight fast
(12 hours) to measure AST, ALT, GGT, albmin, glucose,
insulin, type IV collagen 7s domain, and hyaluronic acid
levels. The serum insulin levels were measured by radio-
immunoassay, and the other values were measured in a
conventional automated analyzer.BMC Gastroenterology 2008, 8:53 http://www.biomedcentral.com/1471-230X/8/53
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Insulin resistance was calculated by the modified homeos-
tasis model assessment of insulin resistance (HOMA-IR),
using the following formula: HOMA-IR = fasting insulin
(μU/ml) × plasma glucose (mg/dl)/405. HOMA-IR was
originally reported by Matthews, and it has since been
modified [28]. This index has been shown to be closely
correlated with the results of the euglycemic-hyperin-
sulinemic clamp method to determine insulin resistance
in type 2 DM patients.
Pentraxin3 measurements
Plasma PTX3 levels were measured with a sandwich ELISA
based on a previously described method [26]. Briefly, the
assay plate was coated with the F(ab')2 fragment of a
monoclonal anti-human PTX3 antibody, PPMX0104
(Perseus Proteomics Inc., Tokyo, Japan) as the capture
antibody and the F(ab')2 fragment of a monoclonal ant-
human PTX3 antibody, PPMX0105 (Perseus Proteomics
Inc., Tokyo, Japan) was conjugated with horseradish per-
oxidase as the detection antibody. Sample dilution (100
μl) was added to the wells. Each calibrator or plasma sam-
ples (10 μl) were added to the wells and incubated for 1
hour with shaking. The wells were aspirated and washed
five times with washing buffer. PPMX0105-enzyme conju-
gate (100 μl) was added to the wells and incubated for 1
hour with shaking. The wells were aspirated and washed
again, and substrate solution was added to each well. After
30 min of incubation, stop solution of the kit (100 μl) was
added. The absorbance at 450 nm was measured with a
microplate reader system. This assay system measured
plasma PTX3 concentration linearly between 0.1 and 20
ng/ml.
Determination of the visceral and subcutaneous fat areas
The abdominal fat distribution of the subjects was deter-
mined by computed tomography (CT), conducted with
the subjects in the supine position in accordance with a
previously described procedure [29]. The subcutaneous
fat area (SFA) and intra-abdominal visceral fat area (VFA)
were measured at the level of the umbilicus in terms of the
CT number, by a standardized method. In brief, a region
of interest was defined in the subcutaneous fat layer by
tracing its contour on each scan, and the attenuation
range for fat tissue was measured in terms of the CT
number (in Hounsfield units).
Pathology
The biopsy specimens of liver tissue were stained with
hematoxylin-eosin, reticulin, and Masson trichrome stain,
and all biopsy specimens were analyzed by one experi-
enced pathologist blinded to the results of clinical data.
Macrovesicular steatosis affecting at least 5% of the hepa-
tocytes was observed in every case, and the cases were clas-
sified as having steatosis or steatohepatitis. In addition to
steatosis, the minimal criteria for the diagnosis of steato-
hepatitis include the presence of lobular inflammation
and either ballooning of cells or perisinusoidal/pericellu-
lar fibrosis in zone 3 of the hepatic acini [30-32]. Subjects
with cirrhosis were defined as cases of NASH-associated
cirrhosis according to a previously proposed clinicopatho-
logical classification [32]. The severity of fibrosis in every
case was scored according to the method of Brunt [33].
The degree of steatosis was graded as follows based on the
percentage of hepatocytes containing macrovesicular fat
droplets: grade 0, no steatosis; grade 1, < 33% hepatocytes
contain macrovesicular fat droplets; grade 2, 33% – 66%
of the hepatocytes contain macrovesicular fat droplets;
grade 3, > 66% of the hepatocytes contain macrovesicular
fat droplets. The stages of fibrosis were expressed on the
following 4-point scale, as follows: stage 0, none; stage 1,
perivenular and/or perisinusoidal fibrosis in zone 3; stage
2, combined pericellular portal fibrosis; stage 3, septal/
bridging fibrosis; stage 4, cirrhosis. Based on this classifi-
cation, the subjects were grouped into 2 groups, a group
with stages 0–2 NAFLD and a group with stages 3–4
NAFLD.
Statistical analysis
Data were expressed as means ± SD, unless indicated oth-
erwise. The statistical analysis was performed with SPSS
12.0 software (SPSS, Inc., Chicago, IL, USA). The t-test or
Wilcoxon rank sum test, as appropriate, was used for uni-
variate comparisons between patient groups. Because
many of the variables were not normally distributed, the
Kruskal-Wallis test was used for comparisons of more
than two independent groups. The diagnostic perform-
ance of the plasma PTX3 level was assessed by analysis of
receiver operating characteristic (ROC) curves. The ROC
curve is a plot of sensitivity versus 1 – specificity for all
possible cutoff values. The most commonly used index of
accuracy is the area under the ROC curve (AUROC), with
values close to 1.0 indicating high diagnostic accuracy.
Calculations of correlation coefficients and linear regres-
sion analysis were used to test for associations between
the variables. Multivariate analysis was performed by
using a binary logistic regression analysis. P values < 0.05
were considered significant.
Results
Patients Characteristics
The histological findings in the liver biopsy specimens of
the subjects with non-NASH (n = 28) and steatohepatitis
(NASH) (n = 42) are shown in Table 1. The clinical and
biochemical characteristics of the NASH patients and
non-NASH patients are shown in Table 2. Marked eleva-
tion of the plasma PTX3 level was observed in the patients
with NASH in comparison with the patients with non-
NASH (p = 0.0021) and healthy control subjects (p =
0.0453). And there was no significance between non-
NASH and control subjects in the plasma PTX3 level (p =
0.2892) (Fig. 1). Significant differences were also found in
the serum AST level (p = 0.0031), ALT level (p = 0.0115),BMC Gastroenterology 2008, 8:53 http://www.biomedcentral.com/1471-230X/8/53
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and hyaluronic acid level (p = 0.0373) between the NASH
patients and those with non-NASH patients (Table 2). The
clinical and biochemical characteristics of stages 0–2
NAFLD group and stages 3–4 NAFLD group are shown in
Table 3. A significantly higher plasma PTX3 (p < 0.0001)
was found in stages 3–4 NAFLD group in comparison
with stages 0–2 NAFLD group (Fig. 2), and a markedly
higher hyaluronic acid level (p = 0.0090) and type IV col-
lagen 7s level (p = 0.0018) and markedly lower serum
albumin level (p = 0.017) and platelet count (p = 0.0134)
were observed between two groups (Table 3).
Hepatic fibrosis and plasma PTX3 levels
Since the plasma PTX3 level was significantly elevated in
the NASH patients in comparison with the non-NASH
patients, and in stages 3–4 NAFLD group in comparison
with stages 0–2 NAFLD group, we investigated the rela-
tionship between stage of fibrosis and the plasma PTX3
levels in the NAFLD patients. Analysis of the plasma PTX3
levels of the NAFLD patients in relation to the histological
stage of fibrosis revealed stepwise increases in the plasma
PTX3 levels as the stages of hepatic fibrosis increased (p <
0.0001, Kruskal-Wallis test) (Fig. 3), and the differences
between stage 0 and stage 3, stage 0 and stage 4, stage 1
and stage 3, stage 1 and stage 4, and stage 2 and stage 4
were significant (p = 0.0009, p < 0.0001, p = 0.0136, p =
0.0001, p = 0.0465, respectively).
Relation between plasma PTX3 and grade of hepatic 
steatosis or grade of necroinflammation
Analysis of the plasma PTX3 levels in relation to the histo-
logical grade of steatosis or grade of necroinflammation
showed no relation between the plasma PTX3 levels and
either of the two other parameters (p = 0.1554, p =
0.1745, respectively by Kruskal-Wallis test).
Receiver operating characteristic (ROC) curves for 
differentiating between NASH and non-NASH based on 
the plasma PTX3 level
To detect NASH compared with non-NASH, the area
under the curve for plasma PTX3 was 0.755 by ROC anal-
ysis (Fig. 4). The best cutoff value for diagnosis of NASH
was also investigated by ROC analysis, and sensitivity,
specificity, positive predictive value (PPV), and negative
predictive value (NPV) were calculated. The results
showed that 1.61 ng/ml was the optimal plasma PTX3
cutoff value for diagnosis of NASH, and its sensitivity, spe-
cificity, PPV, and NPV were 66.7%, 78.6%, 82.4%, and
61.1%, respectively.
Table 1: Histopathological Findings in the NASH patients and 
non-NASH patients
(NASH) (n = 42) Non-NASH (n = 28)
Steatosis grade
12 2 2 0
21 7 6
33 2
Inflammatory activity
04 1 1
12 7 1 7
29 0
32 0
Fibrosis stage
00 2 8
12 1 0
24 0
31 1 0
46 0
Table 2: Clinical and Biochemical Characteristics of the non-NASH Patients and NASH Patients
Non-NASH patients NASH patients P value
Age (years) 49.0 ± 15.3 52.8 ± 13.5 0.2995
BMI (m/kg2) 27.6 ± 5.1 28.9 ± 6.0 0.3989
VFA (cm2) 128.6 ± 55.7 133.3 ± 58.8 0.8031
SFA (cm2) 196.9 ± 61.4 232.5 ± 120.9 0.3765
AST (U/ml) 35.7 ± 17.5 63.4 ± 40.7 0.0031
ALT (U/ml) 56.8 ± 31.5 89.9 ± 55.7 0.0115
FBS (mg/dl) 118.7 ± 39.9 118.2 ± 30.8 0.9586
IRI (ul/ml) 13.6 ± 10.8 14.3 ± 8.2 0.7999
HOMA-IR 3.47 ± 2.64 4.05 ± 2.54 0.4725
HDL cholesterol (mg/l) 50.3 ± 12.6 49.3 ± 11.4 0.7463
LDL cholesterol (mg/l) 133.7 ± 27.0 128.6 ± 39.3 0.5928
Triglyceride (mg/l) 159.0 ± 48.9 162.8 ± 81.9 0.8502
Albumin 4.51 ± 0.28 4.45 ± 0.51 0.6175
Platelet count 25.8 ± 5.7 23.2 ± 8.0 0.1816
Hyaluronic acid (ng/dl) 21.6 ± 15.1 50.1 ± 50.2 0.0373
Type IV collagen 7s (ng/dl) 4.41 ± 0.98 5.14 ± 1.31 0.0611
Data are expressed as means ± SD. VFA: visceral fat area, SFA: subcutaneous fat area, AST: aspartate aminotransferase, ALT: alanine 
aminotransferase, FBS: fasting blood sugar, IRI: immunoreactive insulin, HOMA-IR: homeostasis model assessment of insulin resistance.BMC Gastroenterology 2008, 8:53 http://www.biomedcentral.com/1471-230X/8/53
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ROC curves for differentiating between stages 0–2 NAFLD 
and stages 3–4 NAFLD based on the plasma PTX3 level
To detect stages 3–4 NAFLD compared with stages 0–2
NAFLD, the area under the curves for plasma PTX3 were
0.850 by ROC analysis (Fig. 5). The results of the analysis
showed 2.45 ng/ml to be the optimal plasma PTX3 cutoff
value for diagnosis of advanced NAFLD, and its sensitiv-
ity, specificity, PPV, and NPV were 70.6%, 94.3%, 80.8%,
and 90.9%, respectively.
Multiple regression analysis for demographic factors in the 
NASH patients
We performed the multiple logistic regression analysis by
using the plasma PTX3 levels, AST, ALT, type IV collagen
7s domain, hyaluronic acid, which were significantly ele-
vated factors in NASH patients than in non-NASH
Table 3: Clinical and Biochemical Characteristics of Stages 0–2 and Stages 3–4 NAFLD
Stages 0–2 NAFLD Stages 3–4 NAFLD P value
Age (years) 51.5 ± 13.4 52.8 ± 15.1 0.7564
BMI (m/kg2) 28.1 ± 4.9 30.2 ± 6.7 0.2133
VFA (cm2) 132.1 ± 63.7 135.7 ± 33.4 0.8716
SFA (cm2) 216.9 ± 95.3 256.8 ± 108.2 0.0626
AST (U/ml) 54.6 ± 41.0 58.1 ± 26.9 0.7526
ALT (U/ml) 80.3 ± 49.3 82.4 ± 59.5 0.8903
FBS (mg/dl) 122.9 ± 39.9 112.3 ± 17.8 0.3598
IRI (ul/ml) 13.0 ± 9.06 18.3 ± 9.10 0.0762
HOMA-IR 3.56 ± 2.59 5.16 ± 2.43 0.0677
HDL cholesterol (mg/l) 50.1 ± 12.5 47.8 ± 10.2 0.5277
LDL cholesterol (mg/l) 130.6 ± 33.3 129.8 ± 41.0 0.9430
Albumin (mg/l) 4.55 ± 0.27 4.23 ± 0.66 0.0170
Platelet count (ng/ml) 25.8 ± 6.6 20.0 ± 8.7 0.0134
Hyaluronic acid (ng/dl) 32.7 ± 27.8 72.4 ± 68.1 0.0090
Type IV collagen 7s (ng/dl) 4.65 ± 0.93 5.94 ± 1.53 0.0018
Data are expressed as means ± SD. VFA: visceral fat area, SFA: subcutaneous fat area, AST: aspartate aminotransferase, ALT: alanine 
aminotransferase, FBS: fasting blood sugar, IRI: immunoreactive insulin, HOMA-IR: homeostasis model assessment of insulin resistance.
Plasma PTX3 levels in healthy control subjects, non-NASH  patients, and NASH patients Figure 1
Plasma PTX3 levels in healthy control subjects, non-
NASH patients, and NASH patients. Box plots of 
plasma PTX3 levels showing interquartile range (box), 
median (thick line), range (thin lines) and outliers (circles). 
The length of the box represents the interquatile range 
within which 50% of the values were located. Plasma PTX3 
levels of healthy control subjects, non-NASH and NASH 
patients.
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Plasma PTX3 levels in stages 0–2 and stages 3–4 NAFLD Figure 2
Plasma PTX3 levels in stages 0–2 and stages 3–4 
NAFLD. Box plots of plasma PTX3 levels showing inter-
quartile range (box), median (thick line), range (thin lines) 
and outliers (circles). The length of the box represents the 
interquatile range within which 50% of the values were 
located. Plasma PTX3 levels in stages 0-2 NAFLD and stages 
3-4 NAFLD.
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patients by the univariate analysis. Plasma PTX3 level was
still significant in the NASH patients as compared with
that in non-NASH patients by multiple logistic regression
analysis (Table 4).
Correlation between plasma PTX levels and serum CRP 
levels in the NAFLD patients
We compared the plasma PTX3 levels and serum CRP lev-
els in 70 NAFLD patients. No correlation was found
between plasma PTX3 levels and serum CRP levels (r =
0.220, p = 0.1431) (Fig. 6).
Discussion
The results of this study demonstrated markedly higher
plasma PTX3 levels in the NASH patients in a comparison
with the non-NASH patients, and in stages 3–4 NAFLD as
compared with stages 0–2 NAFLD.
A growing body of evidence has recently been collected
that supports the notion that NAFLD is a feature of the
metabolic syndrome. NAFLD sometimes progresses to cir-
rhosis, it is considered to be the most common form of
chronic liver disease in obese patients. Because there are
few effective treatments for NAFLD, the identification of
important risk factors for disease progression should pro-
vide valuable information in regard to both risk stratifica-
tion and development of risk-reduction strategies [34].
C-reactive protein (CRP) is one of the major acute-phase
proteins and a marker of systemic inflammation. Some
recent reports have suggested that hs-CRP may be an inde-
pendent risk factor for progression of NAFLD [35-37], and
we have reported the clinical usefulness of the measure-
ment of hs-CRP for diagnosis of NASH [10]. PTX3 is a pro-
totypic member of the long pentraxin family and a newly
discovered marker of the acute phase inflammatory
response. PTX3 is structurally related to, but distinct from
classic members of the short pentraxin family, including
from serum amyloid protein and CRP. The short pentrax-
ins CRP and serum amyloid protein are reported to be
produced by the liver as a systemic response to local
inflammation, whereas expression of the long pentraxin
PTX3 is rapidly induced in damaged tissue and may more
directly reflect the tissue inflammatory response and its
expression pattern is more tissue specific [21,38]. The
gene coding PTX3 was originally described as an inter-
leukin (IL)-1β-inducible gene in endothelial cells [14]
and a tumor necrosis factor (TNF)-α inducible gene in
fibroblasts [15]. PTX3 is produced by a variety of cell
types, including monocytes/macrophages and endothe-
lial cells in response to pro-inflammatory stimuli, such as
TNF-α, IL-1β, and lipopolysaccharide (LPS) [39], all of
which are reported to be essential factors in the pathogen-
esis and progression of NASH [40-42]. Patients with
NAFLD are well known to have metabolic syndrome, and
increasing number of metabolic syndrome risk factors is
Relation between Plasma PTX3 levels and fibrosis stage Figure 3
Relation between Plasma PTX3 levels and fibrosis 
stage. Comparison between plasma PTX3 levels in various 
stages of fibrosis. Box plots of plasma PTX3 levels showing 
interquartile range (box), median (thick line), range (thin 
lines) and outliers (circles). The length of the box represents 
the interquatile range within which 50% of the values were 
located. A steady stepwise increase in serum high-sensitivity 
CRP levels was observed with increasing severity of hepatic 
fibrosis (p = 0.0049).
0
1
2
3
4
5
6
7
8
9
0 1 2 3 4
p < 0.0001, Kruskal-Wallis test 
10
P
l
a
s
m
a
 
P
e
n
t
r
a
x
i
n
3
 
(
n
g
/
m
l
)
Fibrosis stage
ROC curve for differentiating steatosis and NASH according  to the plasma PTX3 level Figure 4
ROC curve for differentiating steatosis and NASH 
according to the plasma PTX3 level. ROC curve for dif-
ferentiating between steatosis and NASH on the basis of the 
plasma PTX3 level (area under the curve = 0.719).
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associated with increasing CRP [43,44]. Furthermore,
metabolic syndrome in patients with NAFLD was shown
to be associated with greater histologic severity [45]. How-
ever Inoue K et al. reported that PTX3 is an independent
factor from metabolic risk factors, unlike CRP [46]. And
previous report [21] and this study showed no correlation
between plasma concentrations of PTX3 and CRP.
Because of the similarities and differences between PTX3
and CRP, it is important to assess the usefulness of PTX3
as a novel diagnostic tool for NASH.
We therefore investigated the relationship between
plasma PTX3 levels and several stages of NAFLD, includ-
ing NASH. The results demonstrated that plasma PTX3
levels can be used to reliably differentiate NASH patients
from non-NASH patients. A more detailed study revealed
that plasma PTX3 levels can be used to differentiate
between stages 3–4 NAFLD and stages 0–2 NAFLD, and
that higher plasma PTX3 levels in NAFLD patients are
associated with severe stages of hepatic fibrosis. Plasma
PTX3 levels in healthy volunteers showed around 1.5 ng/
ml, and plasma PTX3 levels in NASH patients were
around 2.6 ng/ml. Furthermore in patients with stage 3–4
NAFLD patients was further elevated (around 3.8 ng/ml).
Thus, we showed that the baseline plasma PTX3 level is
not only a strong clinical marker of NASH, but also of the
severity of liver fibrosis in NAFLD patients. PTX3 is
reported to bind to apoptotic cells inhibiting their recog-
nition by dendritic cells [47], and there is evidence for a
regulatory role of PTX3 in noninfectious inflammatory
reactions [48].
Measurement of plasma PTX3 levels is likely to be useful
for targeted therapies for primary prevention of cardiovas-
cular disease [49]. Similarly, plasma PTX3 may be also
useful for targeted therapy against fibrosis in NASH
patients, because in our study, the plasma PTX3 level was
found to be more significantly elevated in the advanced
stages of NAFLD patient.
Conclusion
This is the first study to demonstrate a consistent and pro-
found elevation of plasma PTX3 levels in NASH patients
whose diagnosis was based on results of liver biopsy, the
gold standard for the diagnosis of NASH. Plasma PTX3
measurements may be noninvasive and appear to show
promise as a means to differentiate NASH from non-
NASH patients, and as a clinical marker of the severity of
liver fibrosis in NASH patients.
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Table 4: Multiple Logistic Regression Analysis of Factors Associated with NASH Compared to non-NASH.
Factor Odds ration 95% CI p Value
plasma PTX3 level (ng/ml) 0.254 0.059 – 0.984 0.0488
AST (U/ml) 0.984 0.910 – 1.064 0.692
ALT (U/ml) 1.008 0.954 – 1.065 0.7699
Type IV collagen 7s domain (ng/ml) 1.128 0.407 – 3.124 0.8171
hyaluronic acid (ng/ml) 0.965 0.908 – 1.025 0.2499
Note: Intercept = -19.493, R2 for entire model = 0.310BMC Gastroenterology 2008, 8:53 http://www.biomedcentral.com/1471-230X/8/53
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